在临床试验设置中接受奥贝胆酸治疗的原发性胆汁性胆管炎患者较真实世界外部对照获得更高的无移植生存率
本研究将POISE随机双盲安慰剂对照试验及其开放标签扩展中接受奥贝胆酸(OCA)治疗的原发性胆汁性胆管炎(PBC)患者,与来自全球PBC和UK-PBC两个登记研究的非OCA治疗外部对照进行倾向性评分匹配比较。6年随访期间,POISE队列209例中5例死亡或肝移植(2.4%),全球PBC对照1381例中135例(10.0%),UK-PBC对照2135例中281例(13.2%)。POISE对比全球PBC和UK-PBC的风险比分别为0.29(95%CI 0.10-0.83)和0.30(95%CI 0.12-0.75)。结论认为试验设置中接受OCA治疗的患者无移植生存率显著高于可比的外部对照。
要点
- 6年随访期间,POISE队列209例中5例死亡或肝移植(2.4%),全球PBC对照1381例中135例(10.0%),UK-PBC对照2135例中281例(13.2%)。
- 主要结局风险比:POISE对比全球PBC为0.29(95%CI 0.10-0.83),POISE对比UK-PBC为0.30(95%CI 0.12-0.75)。
- 全球PBC分析中,肝硬化患者HR为0.20(95%CI 0.03-1.22),无肝硬化患者HR为0.31(95%CI 0.09-1.04),复合终点含肝失代偿时HR为0.42(95%CI 0.21-0.85)。
核心结论
- 试验设置中接受OCA治疗的患者无移植生存率显著高于可比的外部对照。
研究设计与样本
- 研究基于POISE随机双盲安慰剂对照试验及其开放标签扩展,采用倾向性评分生成外部对照,对照来自全球PBC和UK-PBC两个登记研究且符合POISE入选标准。
- 采用逆概率加权Cox比例风险模型评估至死亡或肝移植的时间,额外分析仅用全球PBC数据并将肝失代偿加入复合终点,并分析伴或不伴肝硬化患者的疗效。
主要发现
- 6年随访期间,POISE队列209例中5例死亡或肝移植(2.4%),全球PBC对照1381例中135例(10.0%),UK-PBC对照2135例中281例(13.2%)。
- 主要结局风险比:POISE对比全球PBC为0.29(95%CI 0.10-0.83),POISE对比UK-PBC为0.30(95%CI 0.12-0.75)。
- 全球PBC分析中,肝硬化患者HR为0.20(95%CI 0.03-1.22),无肝硬化患者HR为0.31(95%CI 0.09-1.04)。
- 全球PBC分析中,复合终点包含肝失代偿时HR为0.42(95%CI 0.21-0.85)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The Primary Biliary Cholangitis (PBC) Obeticholic Acid (OCA) International Study of Efficacy (POISE) randomized, double-blind, placebo-controlled trial demonstrated that OCA reduced biomarkers associated with adverse clinical outcomes (ie, alkaline phosphatase, bilirubin, aspartate aminotransferase, and alanine aminotransferase) in patients with PBC. The objective of this study was to evaluate time to first occurrence of liver transplantation or death in patients with OCA in the POISE trial and open-label extension vs comparable non-OCA-treated external controls. METHODS: Propensity scores were generated for external control patients meeting POISE eligibility criteria from 2 registry studies (Global PBC and UK-PBC) using an index date selected randomly between the first and last date (inclusive) on which eligibility criteria were met. Cox proportional hazards models weighted by inverse probability of treatment assessed time to death or liver transplantation. Additional analyses (Global PBC only) added hepatic decompensation to the composite end point and assessed efficacy in patients with or without cirrhosis. RESULTS: During the 6-year follow-up, there were 5 deaths or liver transplantations in 209 subjects in the POISE cohort (2.4%), 135 of 1381 patients in the Global PBC control (10.0%), and 281 of 2135 patients in the UK-PBC control (13.2%). The hazard ratios (HRs) for the primary outcome were 0.29 (95% CI, 0.10-0.83) for POISE vs Global PBC and 0.30 (95% CI, 0.12-0.75) for POISE vs UK-PBC. In the Global PBC study, HR was 0.20 (95% CI, 0.03-1.22) for patients with cirrhosis and 0.31 (95% CI, 0.09-1.04) for those without cirrhosis; HR was 0.42 (95% CI, 0.21-0.85) including hepatic decompensation. CONCLUSIONS: Patients treated with OCA in a trial setting had significantly greater transplant-free survival than comparable external control patients.
引用
- Murillo Perez CF, Fisher H, Hiu S, et al. Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls. Gastroenterology. 2022. PMID: 36150526. doi:10.1053/j.gastro.2022.08.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。